343262-51-1

Basic information

• Product Name: 2-BROMO-5-(METHYLSULFONYL)PYRIDINE
• Synonyms: 2-BROMO-5-METHANESULFONYL-PYRIDINE;2-BROMO-5-(METHYLSULFONYL)PYRIDINE;2-Bromo-5-(methylsulphonyl)pyridine;6-Bromopyridin-3-yl methyl sulphone;Pyridine, 2-bromo-5-(methylsulfonyl)-
• CAS NO: 343262-51-1
• Molecular Formula: C₆H₆BrNO₂S
• Molecular Weight: 236.09
• EINECS: 200-589-5
• Product Categories: Pyridine;Pyridine Series
• Mol File: 343262-51-1.mol

Chemical Properties

• Boiling Point: 387.661 °C at 760 mmHg
• Flash Point: 188.251 °C
• Appearance: /
• Density: 1.679 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.76±0.10(Predicted)
• CAS DataBase Reference: 2-BROMO-5-(METHYLSULFONYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-5-(METHYLSULFONYL)PYRIDINE(343262-51-1)
• EPA Substance Registry System: 2-BROMO-5-(METHYLSULFONYL)PYRIDINE(343262-51-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 343262-51-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMO-5-(METHYLSULFONYL)PYRIDINE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-BROMO-5-(METHYLSULFONYL)PYRIDINE serves as an intermediate in the production of agrochemicals. Its incorporation into these compounds can contribute to the creation of effective pesticides or herbicides.
Used in Organic Compounds Synthesis:
2-BROMO-5-(METHYLSULFONYL)PYRIDINE is utilized as a building block in the synthesis of other organic compounds. Its reactive functional groups make it a versatile component in organic chemistry for creating a wide range of molecules with different applications.
Used in Research and Development Laboratories:
As a compound with intriguing chemical and biological properties, 2-BROMO-5-(METHYLSULFONYL)PYRIDINE is employed in research and development laboratories. Scientists use it to explore its potential applications, understand its reactivity, and develop new methods for its synthesis and utilization.

InChI:InChI=1/C6H6BrNO2S/c1-11(9,10)5-2-3-6(7)8-4-5/h2-4H,1H3

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 124-63-0 methanesulfonyl chloride 
• 624-92-0 Dimethyldisulphide 
• 1068-55-9 isopropylmagnesium chloride 
• 134872-23-4 2-bromo-5-methylthiopyridine 

Downstream Products

• 1185758-51-3 tert-butyl 4-({2-(methoxymethyl)-4-[5-(methylsulfonyl)pyridin-2-yl]phenoxy}methyl)piperidine-1-carboxylate 
• 1402552-66-2 2-(2-{(1S,2R)-2-[1-(cyclohexylacetyl)piperidin-4-yl]cyclopropyl}ethoxy)-5-(methylsulfonyl)pyridine 
• 1402554-71-5 benzyl 4-((1R,2S)-2-(2-(5-(methylsulfonyl)pyridin-2-yloxy)ethyl)cyclopropyl)piperidine-1-carboxylate 
• 1588945-04-3 benzyl 4-((1R,2R)-2-(2-(5-(methylsulfonyl)pyridin-2-yloxy)ethyl)cyclopropyl)piperidine-1-carboxylate 
• 61340-85-0 2-Phenyl-5-methansulfonylpyridin 
• 1201326-81-9 methyl 5-methanesulfonylpyridine-2-carboxylate 
• 31191-07-8 5-(methylsulfonyl)pyridine-2-carbaldehyde 
• 1401098-40-5 tert-butyl 4-((4-(5-(methylsulfonyl)pyridin-2-yl)cyclohex-3-enyloxy)methyl)piperidine-1-carboxylate 
• 1233540-81-2 ethyl 5-{[5-(methylsulfonyl)pyridin-2-yl]oxy}-7-(tetrahydro-2H-pyran-4-yloxy)-1H-indole-2-carboxylate 
• 1233540-78-7 5-(methylsulfonyl)-2-[4-nitro-3-(tetrahydro-2H-pyran-4-yloxy)phenoxy]pyridine 
• 1233540-80-1 ethyl (2E)-2-{[4-{[5-(methylsulfonyl)pyridin-2-yl]oxy}-2-(tetrahydro-2H-pyran-4-yloxy)phenyl]hydrazono}propanoate 
• 1233540-79-8 4-{[5-(Methylsulfonyl)pyridin-2-yl]oxy}-2-(tetrahydro-2H-pyran-4-yloxy)aniline 
• 1310820-43-9 [(3S,4R)-4-(4-chloro-phenyl)-1-(5'-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-carbonyl)-pyrrolidin-3-yl]-methyl-carbamic acid 4-fluoro-phenyl ester 
• 1204128-94-8 2-(4-((2,6-difluoro-4-(5-(methylsulfonyl)pyridin-2-yl)phenoxy)methyl)piperidin-1-yl)-5-ethylpyrimidine 

Relevant articles and documents

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatmen

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart ( e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease.

Furanone derivatives, preparation method and use thereof

The invention relates to a novel selective cyclooxygenase-2 inhibitor compound, a preparation method and use and belongs to the field of chemical drugs. The compound represented by a formula (I) shown in the description can be used for inhibiting cyclooxy

MTH1 INHIBITORS FOR TREATMENT OF CANCER

A compound of formula I, (I) or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer.

MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS

A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.

PIPERIDINE DERIVATIVES USEFUL AS GPR119 AGONISTS

Substituted piperidine compounds and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions and methods of treatment are also included. The present invention relates to G-protein coupled receptor agonists. In particular, the present invention is directed to agonists of GPR 119 that are useful for the treatment of diabetes, especially type 2 diabetes, obesity, the metabolic syndrome and related diseases and conditions.

SUBSTITUTED PYRIDINONE DERIVATIVES AND METHODS FOR MANUFACTURING THE SAME

Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and the compound-containing pharmaceutical composition for treating a metabolic disorder. Specifically, the disclosed compound is represented by [Formula 1]. The compound activates GPR119, and thus can be used for treating metabolic disorders, that is, diabetes mellitus, diabetes mellitus-related diseases, diabetes mellitus-related microvessel complications, diabetes mellitus-related large vessel complications, cardiovascular disorders, metabolic syndrome and its constituent diseases, obesity, and other diseases. In Formula 1, P1, P2, P3, P4, L1, R4, n4, X, Y, Z1 and Z2 are the same as defined above.

NAPHTHYLACETIC ACIDS

The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein W, X, Y, and R1-R7 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

G-PROTEIN COUPLED RECEPTOR AGONISTS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitors

The discovery of heteroaryl-phenyl-substituted pyrazole derivatives as canine selective COX-2 inhibitors is described. Structure-activity relationship (SAR) studies of this class of compounds led to the identification of compound 1 which demonstrated a ca